MK-0646 (dalotuzumab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-0646 (dalotuzumab), covering 2014-11-07 to 2014-11-07. Get the full timeline:
Most recent: Clinical Trial Update: MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer [Phase 2]